AVEO - アベオ・ファ―マシュ―ティカルズ （AVEO Pharmaceuticals Inc.） アベオ・ファ―マシュ―ティカルズAVEOのチャート
AVEOの企業情報
| symbol | AVEO |
|---|---|
| 会社名 | AVEO Pharmaceuticals Inc （アベオ・ファ―マシュ―ティカルズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 アベオ・ファーマシューティカルズ(AVEO Pharmaceuticals Inc.)は癌を治療する会社であり、癌治療法の発見・開発・商業化を中心とする。同社のHuman Responseプラットホームはヒト癌の前臨床モデルを構築する方法であり、同社に癌生物学の洞察を提供し、発見とその癌治療薬の臨床開発で活用されている。平成23年、同社とAstellas Pharma Inc. (Astellas)が提携し、主要製品候補Tivozanibを提供した。Tivozanibはオフターゲット毒性を最小限に抑えながら、血管内皮増殖因子（VEGF）封鎖を最適化するように設計されたすべての3つのVEGF受容体の阻害剤である。平成24年1月、同社は腎細胞癌（RCC）の第一治療法であるグローバルのtivozanib第III相臨床試験のデータ（TIVO-1試験と呼ばれる）を公表した。 アベオ・ファ―マシュ―ティカルズは米国のバイオ医薬品メ―カ―。がんの治療法に注力した新薬の発見、開発、商業化に従事。製品候補には、ERBB3(HER3)受容体をタ―ゲットとする臨床段階モノクロ―ナル抗体である「AV-203」、肝細胞増殖因子の「Ficlatuzumab」、チロシンキナ―ゼ阻害剤の「Tivozanib」などがある。 AVEO Pharmaceuticals Inc. is an oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for cancer patients. AVEO's strategy is to focus its resources toward the development and commercialization of its product candidates in North America, while leveraging partnerships to support development and commercialization in other geographies. AVEO's lead candidate, FOTIVDA® (tivozanib), received U.S. Food and Drug Administration (FDA) approval on March 10, 2021 for the treatment of adult patients with relapsed or refractory renal cell carcinoma (RCC) following two or more prior systemic therapies. FOTIVDA® was approved in August 2017 in the European Union and other countries in the EUSA territory for the treatment of adult patients with advanced RCC. AVEO has previously reported promising early clinical data on ficlatuzumab (anti-HGF IgG1 mAb) in head and neck cancer, pancreatic cancer and acute myeloid leukemia and is conducting a randomized Phase 2 confirmatory clinical trial of ficlatuzumab for the potential treatment of head and neck cancer. AVEO's pipeline of product candidates also includes AV-380 (anti-GDF15 IgG1 mAb). AVEO has previously reported the acceptance of its investigational new drug application in the U.S. for AV-380 and its initiation of a Phase 1 clinical trial for the potential treatment of cancer cachexia. AVEO's earlier-stage pipeline includes monoclonal antibodies in oncology development, including AV-203 (anti-ErbB3 mAb) and AV-353 (anti-Notch 3 mAb). AVEO is committed to creating an environment of diversity and inclusion. |
| 本社所在地 | One Broadway 14th Floor Cambridge MA 02142 USA |
| 代表者氏名 | Michael P. Bailey マイケル・P・ベイリー |
| 代表者役職名 | President Chief Executive Officer Director 社長兼最高経営責任者（CEO） |
| 電話番号 | +1 617-531-2130 |
| 設立年月日 | 37165 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | 2010年 |
| 従業員数 | 19人 |
| url | www.aveooncology.com |
| nasdaq_url | https://www.nasdaq.com/symbol/aveo |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -24.42000 |
| 終値（lastsale） | 2.89 |
| 時価総額（marketcap） | 343997124.83 |
| 時価総額 | 時価総額（百万ドル） 347.47590 |
| 売上高 | 売上高（百万ドル） 6.15500 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 348.11690 |
| 当期純利益 | 当期純利益（百万ドル） -27.88200 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 AVEO Pharmaceuticals Inc. revenues decreased 49% to $1.5M. Net loss decreased 88% to $5M. Revenues reflect Collaboration and licensing revenue decrease of 54% to $1.3M. Lower net loss reflects Change in fair value of PIPE warrant lia increase from $24.4M (expense) to $9.7M (income) Research and Development - Balancing val decrease of 33% to $9.9M (expense) Interest expense. |
AVEOのテクニカル分析
AVEOのニュース
Results from AVEO Pharmaceuticals Inc. (AVEO) show potential 2022/08/31 15:24:00 US Post News
As of Tuesday, AVEO Pharmaceuticals Inc.’s (NASDAQ:AVEO) stock closed at $8.22, up from $7.83 the previous day. While AVEO Pharmaceuticals Inc. has overperformed by 4.98%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, AVEO rose by 31.10%, with highs and lows ranging from $9.37 to $3.06, […]
Nasdaq Drops 200 Points; American Woodmark Shares Spike Higher 2022/08/30 18:32:10 Benzinga
U.S. stocks extended losses toward the end of trading, with the Nasdaq Composite dropping around 200 points on Tuesday The Dow traded down 1.05% to 31,761.62 while the NASDAQ fell 1.67% to 11,817.58. The S&P 500 also fell, dropping, 1.27% to 3,979.32. Also check this: Volatility In Markets Rises Further After US Stocks Extend Last Week''s Losses Leading and Lagging Sectors Health care shares slipped by just 0.5% on Tuesday. Meanwhile, top gainers in the sector included AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO ), up 9% and AN2 Therapeutics, Inc. (NASDAQ: ANTX ) up 5%. In trading on Tuesday, energy shares tumbled by 3.4%. Top Headline The Conference Board’s consumer confidence index rose to 103.2 in August from previous reading of 95.3. Equities Trading UP American Outdoor Brands, Inc. (NASDAQ: AOUT ) shares shot up 17% to $9.06 after B. Riley upgraded the stock from Neutral to Buy and announced an $11 price target. Shares of IN8bio, Inc. (NASDAQ: INAB ) got a boost, shooting 35% to $2.6750 after a Form 4 Filing showed Cavu Advisors purchased 51,214 shares at an average price of $2.02.
AVEO Pharmaceuticals Stock: A Current Assessment On (NASDAQ:AVEO) 2022/08/15 18:25:37 Seeking Alpha
AVEO Pharmaceuticals is seeing good sales growth from its franchise drug that was approved in 2021. Check out my investment analysis of AVEO stock.
AVEO Pharmaceuticals, Inc. (AVEO) CEO Michael Bailey on Q2 2022 Results - Earnings Call Transcript 2022/08/05 02:55:16 Seeking Alpha
AVEO Pharmaceuticals, Inc. (NASDAQ:NASDAQ:AVEO) Q2 2022 Earnings Conference Call August 04, 2022 04:30 PM ET Company Participants Hans Vitzthum - LifeSci Advisors Michael Bailey - President…
AVEO Pharmaceuticals GAAP EPS of -$0.24 beats by $0.04, revenue of $25.3M misses by $0.17M 2022/08/04 20:34:40 Seeking Alpha
AVEO Pharmaceuticals press release (AVEO): Q2 GAAP EPS of -$0.24 beats by $0.04.Revenue of $25.3M (+232.9% Y/Y) misses by $0.17M.AVEO believes that its $77.2M in cash, cash…
Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates 2021/04/02 12:00:21 Benzinga
A slew of drugs, including four new molecular entities, were approved in the month of March. NMEs are drugs that contain active moieties that have never been approved by the Food and Drug Administration previously and are indicators of innovation in drug research. Among the notable approvals that came through in the month were Abecma, the first-ever cell therapy for a type of blood cancer; Fotivda, AVEO Pharmaceuticals, Inc.'s (NASDAQ: AVEO ) oral, next-generation therapy for treating advanced renal cell carcinoma; and KemPharm, Inc.'s (NASDAQ: KMPH ) Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder in patients age six years and older. PDUFA dates are binary events that invariably serve as make-or-break catalysts for stocks. These dates are deadlines by which the FDA reviews a new drug application before announcing its decision concerning the approvability/non-approvability of the drug. Here are the key FDA approvals scheduled for April. Acadia Hopes Against Hope to Get Label Expansion Psychosis Drug Company: ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Type of Application: supplemental new drug application Candidate: pimavanserin Indication: dementia Date: April 3 Pimavanserin, which is marketed under the trade name Nuplazid, has already been approved by the FDA for the treatment of hallucinations associated with Parkinson's disease psychosis.
AVEO Announces Proposed Public Offering of Common Stock 2021/03/22 20:01:00 Business Wire
BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today announced that it has commenced an underwritten public offering of 5,000,000 shares of its common stock. In connection with the offering, AVEO intends to grant the underwriters a 30-day option to purchase up to an additional 750,000 shares of its common stock. All of the shares in the offering are to be sold by AVEO. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering
AVEO Pharmaceuticals Confused? Buy or Sell in volatile market - Analyst report Stock market Insights & financial analysis 2021/03/15 19:03:00 Stock Market Daily
AVEO Pharmaceuticals announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
AVEO Pharmaceuticals, CANbridge AV-203 Licensing Deal Axed, AVEO Regains Ex-North American Rights 2021/03/15 10:41:00 Benzinga
AVEO Pharmaceuticals Inc’s (NASDAQ: AVEO) brief positive news of getting FDA approval for Tivozanib in relapsed kidney cancer this …
The Daily Biotech Pulse: Novavax Vaccine Data, ContraFect Secures BARDA Funding, 2 IPOs 2021/03/12 12:36:15 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 11) Affimed N.V. (NASDAQ: AFMD ) AngioDynamics, Inc. (NASDAQ: ANGO ) Apyx Medical Corporation (NASDAQ: APYX ) AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO ) Axonics Modulation Technologies, Inc. (NASDAQ: AXNX ) BioAtla, Inc. (NASDAQ: BCAB ) BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX ) Bolt Biotherapeutics, Inc. (NASDAQ: BOLT ) Entera Bio Ltd. (NASDAQ: ENTX ) ( announced positive Phase 2 biomarker data for osteoarthritis drug) Harvard Bioscience, Inc. (NASDAQ: HBIO ) IDEAYA Biosciences, Inc. (NASDAQ: IDYA ) Inari Medical, Inc. (NASDAQ: NARI ) Jounce Therapeutics, Inc. (NASDAQ: JNCE ) Longeveron Inc. (NASDAQ: LGVN ) (announced FDA granting expanded access approval for its investigational cell therapy Lomecel-B to a pediatric patient with hypoplastic left heart syndrome) Magenta Therapeutics, Inc. (NASDAQ: MGTA ) Nuvation Bio Inc. (NASDAQ: NUVB )(announced orphan drug designation for NUV-422 in treating malignant gliomas) Renalytix AI plc (NASDAQ: RNLX ) Sol-Gel Technologies Ltd. (NASDAQ: SLGL ) Surmodics, Inc. (NASDAQ: SRDX ) Verrica Pharmaceuticals Inc. (NASDAQ: VRCA ) Down In The Dumps None of the NYSE- and Nasdaq-listed biotech/diagnostic shares hit 52-week lows Thursday.